Area of research
Immunology · Radiology, Nuclear Medicine and Imaging
Research interest
Research focused on Adjuvant and Conjugate, with related work in Epigenetics, Mdm2, Recombinant DNA. Notable publications include 'Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents', 'Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death–Ligand 1 Interaction as Potential Anticancer Agents', and 'The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy'.
Ganglioside GM3 and Lipid A Mimetic Conjugate Combined with EcMPLA and QS-21 as a Potential Vaccine Candidate for Cutaneous Melanoma Immunotherapy
Fully Synthetic TF-Based Self-Adjuvanting Vaccine Simultaneously Triggers iNKT Cells and Mincle and Protects Mice against Tumor Development
Fully synthetic Tn-based three-component cancer vaccine using covalently linked TLR4 ligand MPLA and iNKT cell agonist KRN-7000 as built-in adjuvant effectively protects mice from tumor development
Exploring the catalytic function and active sites of a novel C-glycosyltransferase from Anemarrhena asphodeloides
Fully synthetic Mincle-dependent self-adjuvanting cancer vaccines elicit robust humoral and T cell-dependent immune responses and protect mice from tumor development
Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death–Ligand 1 Interaction as Potential Anticancer Agents
Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection
Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents
Synthesis of a dimer of the repeating unit of type Ia group B<i>Streptococcus</i>extracellular capsular polysaccharide and immunological evaluations of related protein conjugates
The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy